Summary: The herpes simplex virus 1, the virus responsible for cold sores, may account for 50% of Alzheimer’s disease cases. HSV1 causes protein deposits which are characteristic of Alzheimer’s disease. Findings also reveal antiviral treatments can help to reduce the risk of developing Alzheimer’s in those with HSV1.
Source: Frontiers
What causes Alzheimer’s disease? The answer could be right under our noses, says leading expert Professor Ruth Itzhaki. Her latest paper presents a lifetime of research evidence that the herpes virus responsible for cold sores can also cause Alzheimer’s – and new data which show antiviral drugs drastically reduce the risk of senile dementia in patients with severe herpes infections. The review in Frontiers in Aging Neuroscience raises the tantalizing prospect of a simple, effective preventive treatment for one of humanity’s costliest disorders.
The HSV1 theory of Alzheimer’s disease
Herpes viruses are the dreaded ‘gift that keeps on giving’. They remain lifelong in our neurons and immune cells, reactivating and resurfacing in characteristic blisters when we’re run down by stress or illness. Most people are infected by Herpes Simplex Virus 1 (HSV1) by the time they reach old age.
But what happens to infected neurons in our brain during this reactivation?
“HSV1 could account for 50% or more of Alzheimer’s disease cases,” says Professor Itzhaki, who has spent over 25 years at the University of Manchester investigating a potential link.
HSV1 is better known as the cause of cold sores. Itzhaki has shown previously that cold sores occur more frequently in carriers of APOE-ε4 – a gene variant that confers an increased risk of Alzheimer’s.
“Our theory is that in APOE-ε4 carriers, reactivation is more frequent or more harmful in HSV1-infected brain cells, which as a result accumulate damage that culminates in the development of Alzheimer’s.”
Proving the theory
Few countries collect the population data required to test this theory – for example, to find out whether antiviral treatments reduce dementia risk.
In Taiwan however, researchers have done just that. There, 99.9% of the population is enrolled in a National Health Insurance Research Database, which is being extensively mined for information on microbial infections and disease. In 2017-2018 three studies were published describing Taiwanese data on the development of senile dementia – of which Alzheimer’s is the main cause – and the treatment of patients with marked overt signs of infection with HSV or varicella-zoster virus (VZV, the chickenpox virus).
“The striking results include evidence that the risk of senile dementia is much greater in those who are infected with HSV, and that anti-herpes antiviral treatment causes a dramatic decrease in the number of those subjects severely affected by HSV1 who later develop dementia.”
Previous findings from Itzhaki’s own research group provide a mechanistic link which supports these epidemiological findings. They found that HSV1 causes protein deposits characteristic of Alzheimer’s: ‘plaques’ between neurons, and ‘tangles’ inside of them.
“Viral DNA is located very specifically within plaques in postmortem brain tissue from Alzheimer’s sufferers. The main proteins of both plaques and tangles accumulate also in HSV1-infected cell cultures – and antiviral drugs can prevent this.”
Towards a cure
“It should be stressed that the results of these Taiwanese studies apply only to severe HSV1 (or VZV) infections, which are rare,” admits Itzhaki. “Ideally, we would study dementia rates amongst people who have suffered mild HSV1 infection, including herpes labialis (cold sores) or mild genital herpes, but these are far less likely to be documented.”
Although further work is needed to confirm and define a causal link between HSV1 infection and Alzheimer’s, Itzhaki is enthusiastic about the treatment prospects.
“Considering that over 150 publications strongly support an HSV1 role in Alzheimer’s, these Taiwan findings greatly justify usage of antiherpes antivirals – which are safe and well-tolerated – to treat Alzheimer’s disease.
“They also incentivize development of an HSV1 vaccine, which would likely be the most effective treatment.”
This echoes the growing use worldwide of human papillomavirus (HPV) vaccination to prevent cervical cancer – another virus-disease link which emerged in a similar process of research.
Source:
Frontiers
Media Contacts:
Matthew Prior – Frontiers
Image Source:
The image is adapted from the Frontiers news release.
Original Research: Open access
“Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease” Ruth F. Itzhaki. Frontiers in Aging Neuroscience doi:10.3389/fnagi.2018.00324
Abstract
Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease
Strong evidence has emerged recently for the concept that herpes simplex virus type 1 (HSV1) is a major risk for Alzheimer’s disease (AD). This concept proposes that latent HSV1 in brain of carriers of the type 4 allele of the apolipoprotein E gene (APOE-ε4) is reactivated intermittently by events such as immunosuppression, peripheral infection, and inflammation, the consequent damage accumulating, and culminating eventually in the development of AD. Population data to investigate this epidemiologically, e.g., to find if subjects treated with antivirals might be protected from developing dementia—are available in Taiwan, from the National Health Insurance Research Database, in which 99.9% of the population has been enrolled. This is being extensively mined for information on microbial infections and disease. Three publications have now appeared describing data on the development of senile dementia (SD), and the treatment of those with marked overt signs of disease caused by varicella zoster virus (VZV), or by HSV. The striking results show that the risk of SD is much greater in those who are HSV-seropositive than in seronegative subjects, and that antiviral treatment causes a dramatic decrease in number of subjects who later develop SD. It should be stressed that these results apply only to those with severe cases of HSV1 or VZV infection, but when considered with the over 150 publications that strongly support an HSV1 role in AD, they greatly justify usage of antiherpes antivirals to treat AD. Three other studies are described which directly relate to HSV1 and AD: they deal respectively with lysosomal changes in HSV1-infected cell cultures, with evidence for a role of human herpes virus type 6 and 7 (HHV6 and HHV7) in AD, and viral effects on host gene expression, and with the antiviral characteristics of beta amyloid (Aβ). Three indirectly relevant studies deal respectively with schizophrenia, relating to antiviral treatment to target HSV1, with the likelihood that HSV1 is a cause of fibromyalgia (FM), and with FM being associated with later development of SD. Studies on the link between epilepsy, AD and herpes simplex encephalitis (HSE) are described also, as are the possible roles of APOE-ε4, HHV6 and HSV1 in epilepsy.
